GENinCode
Plc
("GENinCode" or the
"Company")
CARDIO
inCode-Score® presentation
at
European Society of
Cardiology Preventive Cardiology Congress
Oxford, UK. GENinCode Plc (AIM:
GENI), the polygenics company focused on the prevention of
cardiovascular disease and ovarian cancer, announces a
presentation by Kaiser Permanente at the European Society of
Cardiology (ESC) Preventive Cardiology congress in Athens, Greece,
on the 'Joint consideration of
low-density lipoprotein cholesterol ("LDL-C") and
polygenic risk for incident coronary heart disease in a
multi-ethnic cohort of 48,881 individuals'
using CARDIO inCode-Score®.1
The Kaiser Permanente Division of
Research study investigated individuals who were part of the
Northern California Genetic Epidemiology Resource in Adult Health
and Aging (GERA) multi-ethnic population-based cohort. The GERA
cohort followed the membership over an average of 14 years, using
CARDIO inCode-Score® to
assess the polygenic risk of coronary heart disease ("CHD") and the
incidence of CHD events in association with LDL-C.
A CHD event was defined as non-fatal
heart attack,
coronary revascularisation
procedures or CHD death.
The study found that LDL-C and
polygenic risk are independently associated with incident CHD, and
that CARDIO inCode-Score® identifies individuals at
the highest risk of
CHD across LDL-C levels. Whilst all patients with elevated LDL-C ought to be treated,
the data indicated that lipid lowering therapies may be more
effective among those with high polygenic risk, as the number
needed to treat (NNT) to prevent one CHD event was much lower in
the high polygenic risk group. The data also indicated that
subjects with a high CARDIO
inCode-Score® should not have LDL-C levels
above 130 mg/dL, as their CHD risk is similar to those with LDL-C
=>190 mg/dL and a low polygenic risk.
The presentation follows the
American Journal of Preventive Cardiology publication earlier this
month indicating individuals with a high
polygenic risk score should be prioritised for lifestyle
advice and where appropriate therapeutic
intervention as they will benefit the most.
Previous data with CARDIO inCode-Score® has shown that, for individuals with a high genetic risk, a
favourable lifestyle is associated with a 52% lower rate of CHD
compared with an unfavourable lifestyle.
The study
underlines the need for 'polygenic risk score' lifetime risk
assessment in conjunction with traditional clinical risk assessment
to optimise preventive care strategies to lower the future risk of
CHD. Polygenic risk assessment can be
undertaken in younger people, before conventional clinical risk
factors (such as high LDL-C levels, high blood pressure, diabetes
etc.) have developed and can be combined with conventional risk
scoring in older people. By doing this clinicians can better
identify those most likely to benefit from lifestyle and
therapeutic intervention.
In the UK around 7.6 million people
live with heart and circulatory disease, which causes 25% of all
deaths annually. Cardiovacular disease (CVD) can be reduced by
identifying and treating individuals at risk, and the NHS 10 Year
Plan (2019) sets out to address CVD prevention.
1. http://www.rns-pdf.londonstockexchange.com/rns/6995M_1-2024-4-30.pdf
For
more information visit www.genincode.com
Enquiries:
GENinCode Plc
|
www.genincode.com
or via Walbrook PR
|
|
Matthew Walls, CEO
|
|
|
|
|
Cavendish Capital Markets Limited
|
Tel: +44
(0)20 7397 8900
|
|
Giles Balleny /Dale Bellis / Michael
Johnson
|
|
Dale Bellis / Michael Johnson
(Sales)
|
|
Walbrook PR Limited
Anna Dunphy / Louis Ashe-Jepson
/ Phillip Marriage
|
Tel: 020
7933 8780 or genincode@walbrookpr.com
|
|
|
|
|
|
About GENinCode:
GENinCode Plc is a UK based company
specialising in genetic risk assessment of cardiovascular disease.
Cardiovascular disease is the leading cause of death and disability
worldwide.
GENinCode operates business units in
the UK, Europe through GENinCode S.L.U, and in the United States
through GENinCode U.S. Inc.
GENinCode predictive technology
provides patients and physicians with globally leading preventative
care and treatment strategies. GENinCode CE marked
invitro-diagnostic molecular tests combine clinical algorithms and
bioinformatics to provide advanced patient risk assessment to
predict cardiovascular disease.
About CARDIO inCode-Score® (CIC-SCORE)
CIC-SCORE is a first in class
in-vitro diagnostic test used to assess an individuals genetic risk
of CHD. The test is based on published clinical
evidence amassed over 15 years which, combined with
traditional clinical risk factors, provides a comprehensive risk
assessment of CHD for use in primary preventive care. GENinCode
labs process patient DNA samples and deliver the CARDIO
inCode-Score® test results to physicians via an online cloud based
algorithmic (AI) reporting system ('SITAB').
CIC-SCORE also addresses the
well-recognised need for improvement in the cardiovascular disease
(CVD) standard of care across ethnicities where individuals from
certain racial and ethnic groups face higher risks of CVD. The
CIC-SCORE test provides an improved estimation of an individual's
risk of heart attack over their lifetime, particularly within a
10-year period post testing when combined with traditional clinical
risk assessment. The CIC-SCORE polygenic risk score enables a major
improvement in patient CVD risk assessment, preventive care and
personalised treatment to reduce the incidence of major adverse
cardiovascular events (MACE), such as heart attack.
About Cardiovascular Disease (CVD):
Heart and circulatory disease also
known as cardiovascular disease (CVD) is the leading cause of death
globally, taking an estimated 17.9 million lives each
year, with Coronary Heart Disease
(CHD) representing
the leading
cause of
death for men, women, and people of most racial and ethnic groups in
the United States. CVD is a group
of disorders of the heart and blood vessels that include
coronary heart disease, cerebrovascular disease, rheumatic heart
disease and other conditions. More than four out of five CVD deaths
are due to heart attacks and strokes, and one third of these deaths
occur prematurely in people under 70 years of age.
By 2030 the global cost of CVD is set to rise
from approximately US$863 billion in 2010 to US$1,044 billion and
is both a major health issue and global economic
burden.
Cardiovascular disease, causes a
quarter of all deaths in the UK and is the largest cause of
premature mortality in deprived areas and is the single biggest
area where the NHS can save lives over the next 10 years. CVD is
largely preventable, through lifestyle changes and a combination of
public health and action on smoking and tobacco addiction, obesity,
tackling alcohol misuse and food reformulation.
The most important behavioural risk
factors of heart disease and stroke are unhealthy diet, physical
inactivity, tobacco use and harmful use of alcohol. The effects of
behavioural risk factors may show up in individuals as raised blood
pressure, raised blood glucose, raised blood lipids, and overweight
and obesity. These "intermediate risks factors" can be measured in
primary care facilities and indicate an increased risk of heart
attack, stroke, heart failure and other complications.
Identifying those at highest risk of
CVDs and ensuring they receive appropriate treatment can prevent
premature deaths. Access to noncommunicable disease medicines
and basic health technologies in all primary health care facilities
is essential to ensure that those in need receive treatment and
counselling.
The current standard of care for
assessing cardiovascular risk is primarily based on traditional
clinical risk factors such as age, sex, smoking, body mass, blood
pressure and cholesterol levels from which individuals are
categorised as being at low, moderate or high risk of a CVD event.
This categorisation is imperfect as CVD events frequently occur in
those thought to be at low or moderate risk. The size of the
populations at low or moderate risk are much larger than those at
high or very high risk so whilst the relative risk of a CVD event
may be small, the absolute number of CVD events in low and moderate
risk populations is much greater than the number of events in
higher risk categories. It is clear
that the earlier in life preventative measures can be put in place
the lower the future risk.
Clinicians have for many years
recognised the importance of prior CVD events within the families
of their patients because genetic factors contribute to the
development of atherosclerosis and a patient's family history has
become a surrogate for their inherited genetic risk. In recent
years, with the advances of genomics, it has proved possible to add
genetic profiling to conventional CVD risk factors, the combination
of the two (genetics and conventional clinical risk factors)
enhancing the predictive capability of patient risk thereby
resulting in a personalised and preventative approach to
CVD.